9 Comments
User's avatar
(Sonu Goswami)'s avatar

Sharp breakdown. Most posts only compare surface-level metrics ... this went deeper into NDR, ARPA, EBITDA margins, and even market motion. Really helps anyone evaluating healthcare SaaS. Appreciate the research-driven lens.

Archetype Capital's avatar

Appreciate your comment!

Matt Newell's avatar

Why does this company even need to pay down debt? Their interest is covered 4x by EBIT. Retiring debt at 6.5% is hardly value accretive when you could be buying the stock at a 20% earnings yield. Thoughts?

Archetype Capital's avatar

buybacks would be better at these levels, would supercharge the F123 out of this stock. Management have just guided debt paydown instead, I hope we see opportunistic buybacks.

Matt Newell's avatar

Weird choice from management then - I wonder what’s driving it. Anything that trades at 5x sustainable earnings is interesting to me - I’ll take a look at it.

Archetype Capital's avatar

Interested to hear what you find!

Gator's avatar

Fantastic write up. Love how specific the markers are you're looking for if things go wrong 10/10

anon's avatar

caution, for oligopoly players in software (especially healthcare), open exchange standards are :

1. a revenue source for 'connection\transaction'

2. a near guaranteed path for taking these feature in-house from competitors

rarely has any company been as aggressive as epic in this strategy.

YJL21's avatar

agreed, how can we get comfortable with the disintermediation risk?